Evoke Pharma Inc EVOK
We take great care to ensure that the data presented and summarized in this overview for Evoke Pharma Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EVOK
View allLatest Institutional Activity in EVOK
Top Purchases
Top Sells
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Insider Transactions at EVOK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2020
|
David A Gonyer CEO |
SELL
Open market or private sale
|
Direct |
23,954
-6.59%
|
$47,908
$2.94 P/Share
|
|
Dec 11
2020
|
David A Gonyer CEO |
SELL
Open market or private sale
|
Direct |
48,046
-11.67%
|
$96,092
$2.9 P/Share
|
|
Dec 11
2020
|
Matthew J D'Onofrio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,357
-12.44%
|
$80,714
$2.91 P/Share
|
|
Dec 10
2020
|
Matthew J D'Onofrio Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,643
-1.71%
|
$11,286
$2.95 P/Share
|
|
Dec 09
2020
|
Matthew J D'Onofrio Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,000
+12.23%
|
$0
$0.4 P/Share
|
|
Dec 09
2020
|
David A Gonyer CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+14.88%
|
$0
$0.4 P/Share
|